Abstract. In order to study whether somatostatin reduces posthypoglycemic insulin resistance, hypoglycemia was induced between 7.00 and 8.00 h by an iv infusion of insulin with and without somatostatin (250 \g=m\g/h) in 6 male patients with insulin-dependent diabetes mellitus (IDDM). Exogenous glucagon was infused to substitute for the suppression of its endogen- 
hypoglycemic studies similar nadir blood glucose levels were achieved and hypoglycemia evoked the same increase of plasma epinephrine and cortisol, whereas plasma glucagon remained at its basal level. The growth hormone response to hypoglycemia was suppressed by somatostatin. At the onset of the SIGIT, the plasma levels of the counterregulatory hormones had returned to basal, and blood glucose and plasma free insulin concentrations were almost identical. During the SIGIT there were no differences in plasma free insulin or counterregulatory hormone levels. Insulin resistance, as seen following hypoglycemia, was not demonstrable in the study with somatostatin. It is concluded that somatostatin reduces insulin resistance following hypoglycemia in patients with IDDM. It is therefore suggested that an analogue with a specific GH release inhibiting property may be useful in reducing glycemic instability when given as adjunct therapy to insulin in patients with labile glycemic control.
Intensified insulin therapy in patients with insu¬ lin-dependent diabetes mellitus (IDDM), aiming at near normoglycemia, is associated with an enhanced risk for the occurrence of hypoglycémie episodes (Pramming et al. 1985) . It is still a matter of controversy whether such hypoglycémie epi¬ sodes may cause labile glycémie control by pro¬ moting posthypoglycemic insulin resistance (Ras¬ kin 1984) . We have previously demonstrated insu¬ lin resistance to occur some 4-6 h after a hypo¬ glycémie event (Kollind et al. 1987a (Kollind et al. , 1988a , and that growth hormone is of importance in this respect (Kollind et al. 1988b) . Against this back¬ ground the use of the GH release inhibiting hormone somatostatin may seem a fruitful thera¬ peutic option in an attempt to circumvent this metabolic consequence of hypoglycemia. There¬ fore, the aim of the present study was to assess the effect of somatostatin, administered during hypo¬ glycemia, on posthypoglycemic insulin resistance in IDDM patients. In order to simulate the action of a specific inhibitor of GH secretion, exogenous glucagon was given to compensate for the somatostatin-induced suppression of glucagon secretion.
Patients and Methods
Six male patients with IDDM, age 22-37 years, without residual beta-cell function (C-peptide <0.1 nmol/1 after a mixed meal) were studied. The duration of their diabetes was 9.4 ± 1.9 years, the body mass index (Thomas et al. 1976) hypoglycemia induced by insulin. Study C: hypoglycemia induced by insulin, with co-infusion of somatostatin and glucagon. In study A the blood glucose level was kept at 5-6 mmol/1 by a variable iv insulin infusion, whereas in study B, a constant rate iv insulin infusion (f.5 mlU kg"1 · min"1) was started at 7.00 h and maintained until a blood glucose level below 2.5 mmol/1 was reached. After 20 min the hypoglycémie reaction was stopped by an iv bolus injection of glucose (0.15 g/kg). Sixty min after the hypoglycemia, the variable iv insulin infusion was restarted, its rate being adjusted every 5-15 min, in order to keep the blood glucose level close to 6 mmol/1 at the start of the SIGIT. In study C, insulin was given as in study B, and the same glucose dose was applied to stop the hypoglycémie reaction. In addition, from 7.00 to 11.00 h somatostatin (250 µg/h, Ferring AB, Sweden) and glucagon (Novo Industri Vs, Denmark) were in¬ fused through separate iv lines. Glucagon was infused at a rate of 1.0 ng-kg"1· min-1, except during maximal hypoglycemia, when its rate was temporarily increased to 1.5 ng-kg"1-min-1 for 20 min. In order to simulate the same blood glucose profile as in study B, additional iv 
Results
The mean blood glucose during the 24-h period preceding each experiment was close to identical in studies A, and C (8.9 ± 0.6, 9.0 ± 0.5 and 8.8 ± 0.3 mmol/1), and the corresponding M-val¬ ues were similar (18.1 ± 2.2, 17.0 ± 4.0 and 20.7 ±2.2).
Between 7.00 and 11.00 h on day 2, plasma epinephrine, cortisol, GH and glucagon were in the normal range in study A (Fig. 1) . Insulininduced hypoglycemia (study B) caused the ex¬ pected rises of plasma epinephrine, cortisol and GH, whereas no significant glucagon rise was registered. In study C, the magnitude of hypo¬ glycemia and the corresponding increases of plasma epinephrine and cortisol were similar to those seen in study B, and plasma glucagon re¬ mained at its basal level. The plasma GH levels, calculated as the area under the respective curve between 7.00 and 11.00 h (pre-SIGIT period), were 9.7 ± 2.2, 78.6 ± 7.2 and 3.4 ± 1.8 pg/1 per h in the study A, and C, respectively. 9.6 ± 0.3** 9.2 ±0.5 8.4 ± 0.5*** 12.0 ± 0.5** 10.9 ±0.8 9.4 ± 0.9*** 12.9 ± 0.7*·** 11.7 ±0.7 9.7 ± 1 1*** 12.6 ± 0.6*>** 10.8 ± 0.9 9. The total amount of insulin given between 7.00 and 11.00 h in study A, and C was 2.1 ± 0.3, 7.5 ± 0.6 and 6.8 ± 0.6 IU, respectively. Although similar amounts of insulin were given in studies and C, significantly more glucose was given prior to the SIGIT in study C as compared with study (152 ± 16 vs 38 ± 2 g, < 0.001). At the start of the SIGIT the plasma levels of epinephrine, glu¬ cagon, cortisol and GH were at basal levels, and almost identical concentrations of blood glucose and plasma free insulin were registered. During the SIGIT, plasma free insulin, GH, cortisol and glucagon did not differ in the three experiments (Fig. 1) .
In study as compared with study A, a higher blood glucose level (P < 0.05) was seen over the last hour of the SIGIT period ( Fig. 1 and Table 1 ), whereas in study C the blood glucose level was lower than in study ( < 0.05) during the last 3 h of the SIGIT period. In study C, as compared with study A, the blood glucose concentration was diminished over the whole SIGIT period, reach¬ ing statistical significance at t2.00, 13.00 and 14.00 h (P< 0.05) ( Table 1) .
Discussion
Total insulin resistance can be estimated in vivo over several hours with the modified SIGIT, a method with good accuracy and reproducibility (Kollind et al. 1987a (Kollind et al. , 1988b (Campbell et al. 1985a ), somatostatin has been successfully used to prevent this phenomenon to occur (Campbell et al. 1985b) . Furthermore, since somatostatin also may modulate the intestinal abSorption of nutrients (Wahren & Feiig 1976) , a beneficial effect of somatostatin in reducing post¬ prandial hypoglycemia has been speculated upon (Bratusch-Marrain et al. 1981 (Kollind et al. 1987b (Kollind et al. , 1988a (Clausen et al. 1987 ). On the other hand, suppression of the GH-secretion could explain such an effect, as indicated above, since in the experiment with somatostatin, the plasma GH concentration was significantly diminished also in the pre-SIGIT period. Our data therefore support previous ob¬ servations that suppression of the basal GH secre¬ tion enhances insulin sensitivity (Campbell et al. 1985b ).
In conclusion, we suggest that an analogue of somatostatin which exclusively suppressess GH secretion could be of interest as an additional therapeutic agent in the treatment of diabetes as such a peptide might reduce the hypoglycémie rebound after hypoglycemia in diabetic patients with metabolic brittleness.
